Health Policy

Why this matters in health economics

Chapter 1.3 — Market Failure explains why health care cannot be left to a market: information is asymmetric, insurance pools unravel, one person's vaccination protects another, and the person who advises care often profits from it. This chapter is about what a government does next. Every failure catalogued there implies a response, and the response is never free — it costs public money, constrains someone's liberty, redistributes from one group to another, and can misfire. Policy is the point at which economic diagnosis becomes an act of the state with winners and losers.

The stakes are large and concrete. A sugary drink tax changes what millions of people can afford to drink and moves revenue between an industry, a treasury, and a health budget. A decision to fund prevention rather than treatment reallocates money between people who are ill now and people who might fall ill later — often a transfer between the visible and the statistical, the present and the future. A regulation that mandates safer staffing or cleaner air imposes real costs on providers and firms in exchange for health gains that are diffuse and hard to attribute. These are economic decisions dressed as political ones, and getting the economics wrong wastes money and, at scale, costs lives.

Health policy also carries a distinctive burden of legitimacy. Because interventions restrict choice, tax consumption, or spend money raised by force of law, they must be justified not only by whether they work but by whether they are fair and whether the public will accept them. A director who treats policy as a purely technical optimization — the intervention with the best cost per quality-adjusted life year (QALY) wins — will be blindsided by the politics of prevention, the industries that lobby against fiscal levers, and the equity objections that sink otherwise sound proposals. This chapter is about doing the economics honestly while respecting that policy is made in public.

Core concepts

Health policy is the set of decisions, plans, and actions a government or organization takes to pursue population health goals. It spans how care is financed and organized — the typologies of financing and provider payment are the subject of Chapter 3.1 — Health Systems — and, the concern of this chapter, the instruments government uses to correct market failures: regulation, taxation, subsidy, information, and public provision.

The classic account of policy-making is a cycle: problem identification, option appraisal, decision, implementation, and evaluation. The reality is messier — windows of political opportunity open and close, evidence arrives late, and the same reform is passed for reasons unrelated to the analysis that justified it. Evidence-based policy is the aspiration that decisions should be grounded in the best available evidence of effect and cost-effectiveness; the honest version accepts that evidence is one input among values, budgets, and feasibility, and that its job is to narrow the space of defensible choices rather than to dictate one.

Government's toolkit runs along a spectrum of coercion. At the lightest touch sits information — labelling, public information campaigns, quality reporting — which corrects asymmetry without removing choice. Next come fiscal and pricing levers that change relative prices while leaving the choice formally free. Then regulation: rules that mandate or prohibit, from licensing and safety standards to advertising bans. At the heaviest sits direct public provision and monopoly purchasing. A guiding principle is proportionality — use the lightest instrument that will actually shift behaviour at the margin, and escalate only when it will not.

The fiscal levers deserve their own vocabulary. A Pigovian tax is a tax set equal to the external cost a behaviour imposes on others, designed to make the private price reflect the social cost — the textbook remedy for a negative externality. Taxes on tobacco, alcohol, and sugar are often described this way, though most are better understood as a hybrid: they partly correct externalities (the costs a drinker or smoker imposes on others), partly correct "internalities" (the future costs people impose on their own health because of present bias, a behavioural argument developed in Chapter 4.1 — Behavioural Economics), and partly just raise revenue. A sin tax is the political name for the same instrument. Design decides everything: whether the tax is levied on volume or on sugar content, whether it is passed through to consumers, and whether the demand is elastic enough to move consumption rather than merely collect money.

Preventive healthcare and the wider field of public health supply much of policy's rationale. Prevention is not one activity but three, and they do not share an economics. Primary prevention stops disease arising at all — vaccination, clean water and sanitation, tobacco and alcohol control, road safety. Secondary prevention detects and treats disease early, before symptoms or complications — screening programmes and case-finding. Tertiary prevention limits the damage of established disease and prevents recurrence — rehabilitation, secondary-prevention medication, structured management of long-term conditions. The three differ in what they cost, in how long the payoff takes, and in whether the beneficiary is an identifiable patient or a statistical person, so they cannot be appraised as a single category.

Prevention economics then asks a hard question that intuition gets wrong: prevention is not automatically cheaper than cure. Some preventive programmes are genuinely cost-saving — a handful of vaccinations, and some screening for high-prevalence conditions, pay for themselves — but many buy health at a positive cost, exactly like a treatment, and must clear the same cost-effectiveness bar and be appraised by the same methods (the evaluation discipline belongs to Chapter 2.1 — Economic Evaluation). Treating the maxim "prevention is better than cure" as if it also meant "prevention is cheaper than cure" is one of the more expensive errors in health policy: it funds programmes on a promise of savings that never arrive, and it discredits the sound ones when the promise fails.

Prevention also carries a structural puzzle that shapes both its economics and its politics — the prevention paradox, named by the epidemiologist Geoffrey Rose. A preventive measure that brings a large benefit to a whole population may offer very little to each participating individual, because most people who take the pill, wear the belt, or accept the screening were never going to be the case it prevented. This forces a choice between two strategies. A high-risk strategy concentrates effort on the minority at greatest risk, where the benefit relative to cost per person is favourable and the intervention feels worthwhile, but it reaches only a small share of total cases, because most cases arise in the large, low-risk majority. A population strategy shifts the whole risk distribution a little — a modest tax, a reformulation target, a changed default — and can prevent far more cases in aggregate, yet each individual's gain is tiny, motivation is hard to sustain, and even a small harm spread across millions can offset the good. Fiscal and regulatory levers are usually population strategies; screening and case-finding are usually high-risk ones; the two are appraised, sold, and resisted in completely different ways.

The last distinctive feature is time. Prevention's costs land now while its benefits arrive years or decades later, discounted heavily and often banked by a different budget or department — the wrong-pockets problem. This collides with the annual budget cycle and with budget-impact tests, which reward interventions that pay back inside the planning horizon and penalize long-lag investment even where its lifetime value is high; the affordability-versus-value distinction is the subject of Chapter 2.5 — Budget Impact and Affordability, and the same long-lag return-on-investment problem afflicts digital tools in Chapter 5.2 — Digital Health Economics. Practitioner tools exist to make the long view concrete: public-health return-on-investment (ROI) calculators, such as those published for public-health teams by GOV.UK and the former Public Health England, estimate the payback of a prevention programme over realistic multi-year horizons and by population group, so a commissioner can see both what it costs this year and what it returns over ten. Used honestly, they reframe the question from "does this save money next year" to "is this good value over the horizon on which it actually works."

Two further concepts frame the risks. Regulatory capture is the tendency for the industries a regulator oversees to shape the rules in their own favour, turning a public instrument to private ends. And health technology assessment (HTA) — the systematic appraisal of the value of a health technology — is the institutional machinery through which many governments translate economic evidence into coverage and pricing decisions, the clearest example of evidence-to-policy translation in routine operation.

Best practices

1. Start from the specific market failure, not the fashionable instrument. A policy is a remedy, and a remedy needs a diagnosis (the catalogue is in Chapter 1.3 — Market Failure). If the failure is a negative externality, a corrective tax or a standard fits; if it is asymmetric information, labelling or quality reporting may be enough; if it is an unravelling insurance pool, the answer is mandates or pooling, not a tax. Naming the failure first stops you reaching for a sugar tax when the problem is really monopoly pricing, or for more information when people already know and cannot act.

2. Escalate coercion only as far as the behaviour requires. Order your options from least to most coercive — information, price signals, defaults, mandates, prohibition — and prefer the lightest that will move behaviour at the margin where it actually changes. Lighter instruments are cheaper, more acceptable, and easier to reverse if they fail; heavier ones buy larger effects at the cost of liberty, political capital, and enforcement burden. The proportionality test is not a preference for doing less, but a discipline for spending coercion where it pays.

3. Design fiscal levers around the elasticity, not the slogan. A Pigovian tax only changes behaviour if demand responds to price and if the tax is passed through to the shelf price. Tax the harmful ingredient rather than the product where you can — a levy on sugar content, tiered so it rewards reformulation, does double duty by pushing manufacturers to change recipes as well as pushing consumers to buy less. Watch for substitution to untaxed alternatives and cross-border purchasing, and decide in advance whether success looks like less consumption or more revenue, because a tax cannot maximize both.

4. Confront the regressivity of consumption taxes head-on. Taxes on tobacco, alcohol, and sugary drinks take a larger share of income from poorer households, who also often bear more of the underlying disease — a genuine equity tension, not a talking point (the framing is developed in Chapter 3.4 — Equity). The defensible answer is to look at the whole package: poorer groups tend to be more price-responsive and so gain more of the health benefit, and earmarking the revenue for services or subsidies that reach the same households can offset the financial burden. State this openly; a proposal that pretends the regressivity away will lose the argument the moment an opponent names it.

5. Appraise prevention with the same rigour as treatment, and never assume it saves money. Some prevention is cost-saving; much of it buys health at a positive cost per QALY, which is a perfectly good reason to fund it but a different claim from "it pays for itself." Use the evaluation discipline of Chapter 2.1 — Economic Evaluation, and be explicit about the long lags: benefits that arrive decades later, discounted heavily, will look weaker than an intuition that prevention is obviously worth it. Overclaiming savings is the fastest way to discredit a good preventive programme when the savings do not materialize on schedule.

6. Follow the money and the time across budget boundaries. Prevention's costs and benefits routinely fall in different places — a housing or education programme that improves health, a local government levy that relieves a national hospital budget years later. Where the payer of the cost is not the beneficiary of the saving, good policy stalls even when the aggregate case is strong. Name the "wrong-pockets" problem explicitly and design the financing to bridge it, through pooled budgets, transfers, or outcome-based arrangements, or the analysis will be right and ignored.

7. Build the evaluation into the policy before it launches. A policy that cannot be evaluated cannot be improved or defended, yet reforms are routinely rolled out everywhere at once, destroying any comparison group. Where feasible, phase implementation to create a natural experiment, pre-register the outcomes and the analysis, and commission independent appraisal using the causal-inference methods of Chapter 2.3 — Health Econometrics. The tobacco and sugar-tax literatures are credible precisely because staggered adoption across jurisdictions allowed before-and-after and cross-border comparison.

8. Use health technology assessment as standing evidence-to-policy machinery. Health technology assessment turns economic evidence into routine, transparent, contestable decisions — in England through the National Institute for Health and Care Excellence (NICE), in Germany through IQWiG, in Australia through the Pharmaceutical Benefits Advisory Committee, and increasingly through joint European appraisal. An institution that applies a consistent method and publishes its reasoning does what ad hoc ministerial decisions cannot: it makes the opportunity cost visible and defends decisions against lobbying. The rationing choices HTA informs are the subject of Chapter 3.3 — Rationing.

9. Anticipate industry response and design against capture. The industries a policy targets will lobby, litigate, reformulate, relocate, and fund counter-evidence, and a regulator can be slowly turned to serve them (regulatory capture). Assume strategic behaviour in your modelling — a volume tax invites downsizing packs; an advertising ban shifts spend to sponsorship — and build in transparency of lobbying, arm's-length institutions, and periodic external review. Treaties such as the World Health Organization's Framework Convention on Tobacco Control exist partly to hold a line against industry pressure that no single government could hold alone.

10. Combine instruments; single levers rarely work alone. The clearest public-health successes stack measures rather than relying on one. Tobacco control pairs taxation with advertising bans, smoke-free laws, plain packaging, and cessation support, each reinforcing the others; obesity policy pairs fiscal levers with reformulation targets, marketing restrictions, and labelling. Model the package, expect interactions, and sequence the components so that early, popular measures build the credibility to pass harder ones.

11. Run a proportionate regulatory impact assessment before you regulate. Before imposing a rule, estimate its costs and benefits, its distributional effects, and the burden of compliance and enforcement — a regulatory impact assessment (RIA) in the tradition of appraisal guidance such as the United Kingdom's Green Book. Weigh the cost of the intervention against the size of the failure it corrects; a rule that costs more than the harm it prevents is a net loss even if it is popular. Include the counterfactual and the option of doing nothing, so the bar for coercion is honestly set.

12. Legislate for reversibility, monitoring, and sunset. Policies misfire, contexts change, and yesterday's remedy becomes today's distortion. Build in review dates, data collection from day one, and the legal ability to adjust rates, tighten standards, or withdraw a measure that is not working. A tax with no mechanism to update its rate erodes with inflation; a standard with no review ossifies; a subsidy with no exit outlives its rationale. Designing the off-ramp is as much a part of good policy as designing the intervention.

Questions to discuss with your team

1. For the health problem in front of us, which market failure are we actually correcting, and is our proposed instrument the proportionate answer to it? This question forces the diagnosis before the prescription. Teams reach for whatever instrument is politically available — a tax because a treasury wants revenue, a campaign because it is cheap and visible — without asking whether it matches the failure. Work through the catalogue in Chapter 1.3 — Market Failure: is this an externality, an information gap, an agency problem, an unravelling pool? Then place your instrument on the coercion spectrum and ask whether a lighter one would move behaviour or a heavier one is genuinely needed. An honest answer names the failure precisely, admits where the fit is imperfect, and can say why the chosen instrument is proportionate rather than merely convenient.

2. Who bears the cost of this policy, who reaps the benefit, and how far apart in time and in society do the two sit? Almost every health policy transfers resources — between rich and poor, present and future, one budget and another, an industry and a treasury. A consumption tax lands hardest on poorer households; a prevention programme spends now for benefits a different department banks in a decade. Map the incidence explicitly: name the losers, not just the winners, and be candid about the "wrong-pockets" and long-lag problems that make good policy stall. The honest answer does not pretend a policy is costless or universally beneficial; it states the distribution, tests whether it is defensible on equity grounds (Chapter 3.4 — Equity), and designs mitigation — earmarking, exemptions, cross-budget transfers — into the proposal rather than bolting it on later.

3. How will we know whether this policy worked, and did we design that evaluation before or after launch? Most policies are rolled out in a way that makes them impossible to evaluate — everywhere at once, with no comparison group, no baseline data, and no pre-agreed outcome. The result is that success and failure become matters of assertion, and the next decision is made on anecdote. Ask concretely: what would count as success, over what horizon, measured how; can we phase the rollout to create a comparison; will we pre-register the analysis and commission it independently (the methods are in Chapter 2.3 — Health Econometrics). The tension is that good evaluation slows launch and risks producing an inconvenient answer. An honest reckoning accepts that risk, because a policy no one can evaluate cannot be improved, defended against repeal, or learned from.

4. If we are funding prevention, are we selling it on cost savings or on value — and have we been honest about when the benefits actually land? Prevention is the part of the toolkit most often oversold, because the maxim "prevention is better than cure" quietly becomes "prevention is cheaper than cure" — a different and usually false claim. Some prevention pays for itself; much of it buys health at a positive cost, exactly like a treatment, and should clear the same cost-effectiveness bar (Chapter 2.1 — Economic Evaluation). Ask which of the three preventions this is — primary, secondary, or tertiary — because they do not share an economics, and whether it is a population strategy or a high-risk one, because the prevention paradox means the two are appraised against completely different yardsticks. Then confront the timing honestly: the costs land this year while the benefits arrive years later, discounted heavily and often banked by a different budget through the wrong-pockets problem. An honest answer states the real basis for funding, uses a return-on-investment horizon that matches when the benefit accrues rather than the annual budget cycle, and refuses to promise savings the evidence does not support — because overclaiming is the fastest way to discredit a sound programme when the savings fail to arrive on schedule.

5. How will the industry we are targeting respond, and have we designed against being slowly captured by it? Policy analysis routinely models behaviour as static and treats the regulator as neutral, when neither holds: a taxed or regulated industry will reformulate, downsize packs, substitute to untaxed alternatives, relocate, litigate, and fund counter-evidence, and over time it can turn the rules to its own advantage through regulatory capture. Work through the likely strategic responses to each instrument — a volume tax invites smaller packs, an advertising ban shifts spend to sponsorship — and ask whether the policy still works once the target has adapted. Then ask the harder institutional question: who writes the detailed rules, who reviews them, and what stops the regulated from steering both. The defences are structural — transparency of lobbying, arm's-length institutions, periodic external review, and international frameworks such as the Framework Convention on Tobacco Control that hold a line no single government could hold alone. An honest answer treats industry response as a modelling input rather than a surprise, and builds the anti-capture machinery in from the start rather than bolting it on after the first scandal.

6. Have we built the off-ramp — review, monitoring, and the power to adjust or withdraw — into the policy before it launches? Policies misfire, contexts change, and yesterday's remedy becomes today's distortion, yet measures are routinely legislated with no review date, no data collection, and no legal power to change course. A tax with no mechanism to update its rate erodes with inflation; a standard with no review ossifies; a subsidy with no exit outlives its rationale. Ask what evidence we will collect from day one, when the measure is scheduled for review, and who has the authority to tighten, loosen, or repeal it. The tension is that designing an off-ramp admits the policy might fail, which is politically uncomfortable when you are trying to build support to pass it. An honest answer treats reversibility as a feature rather than an admission of doubt, because the alternative is a book of dead-letter rules no one can update, and a credibility cost when an obviously spent measure cannot be removed.

In practice: a health economics example

The Ministry of Health of the fictional upper-middle-income Emirate of Qamar faces a diabetes and obesity burden among the highest in its region, with sugar-sweetened beverage consumption well above the global average. A reform team proposes a levy on sugary drinks. The finance ministry is interested chiefly in the revenue; the health minister wants the disease numbers to fall; the beverage industry, a significant local employer, is already briefing against it. The team's economist insists the first question is not the rate but the objective, because a tax cannot maximize both revenue and health.

The team designs the levy as a tiered tax on sugar content rather than a flat charge on volume, with a higher band above a sugar threshold and a lower band below it, and a zero band for reformulated and unsweetened drinks. The logic is that a content-based, tiered structure works on two margins at once: it raises the shelf price for consumers, and it gives manufacturers a reason to reformulate to drop into a lower band — a response observed where similar tiered designs have been used elsewhere. Modelling suggests much of the early health gain will come from reformulation rather than from consumers buying less, which also tempers the regressivity, because reformulation lowers sugar for everyone regardless of income.

Regressivity is the sharpest objection, and the team meets it directly. The levy will take a larger share of income from poorer households, who also carry more of the diabetes burden. The team's answer has three parts: poorer households are more price-responsive and so gain a larger share of the health benefit; the revenue will be earmarked for primary care and school nutrition in lower-income districts; and staple foods are untouched. They are candid that this does not erase the burden, only offsets it, and that the earmark is a political commitment a future budget could break. They also model industry strategy — pack downsizing, substitution to untaxed juices, cross-border purchasing from a neighbouring emirate — and build in monitoring for each.

Crucially, the team designs the evaluation before launch. Because the levy will apply nationally on a fixed date, there is no internal comparison group, so they arrange to track sugar content of the product range (to detect reformulation), household purchasing by income quintile, and cross-border sales, with a pre-registered analysis comparing trends against neighbouring markets without a levy. They legislate a three-year review with power to adjust the thresholds and rates, and an explicit revenue-tracking duty so the earmark can be audited. The proposal that reaches the cabinet is therefore not "a sugar tax" but a package: a tiered content levy, an earmarked revenue commitment, a monitoring and evaluation plan, and a review clause. The economist's closing note to the minister is that the tax alone will move the numbers only modestly, and that the case for it strengthens sharply when it is paired with marketing restrictions and clear labelling — a combined package, appraised together, rather than a single lever expected to carry the whole burden.

Four sector lenses

Startup

A digital health start-up rarely sets policy, but it lives or dies by it. A company selling a diabetes-prevention app or a remote-monitoring service depends on whether a national payer or regulator recognizes its category, sets an evidence standard it can meet, and creates a reimbursement route. The smart early move is to read the policy terrain — HTA evidence requirements, procurement rules, data regulation — as a product constraint from day one, and to generate the kind of evidence policy bodies will accept rather than the marketing evidence investors like. Start-ups can also be the vehicle a government uses to pilot a policy, which makes the design of the evaluation (best practice 7) their commercial interest as much as the state's.

Small business

An established small provider — a general-practice partnership, a single clinic, a community pharmacy, a care home, or a small device supplier — is where policy meets the front line, and it is the actor with the least slack to absorb it. Unlike a start-up, it is not chasing a category or an exit; it runs a steady book of patients or customers and needs the rules to be stable, proportionate, and cheap to comply with, because every hour of paperwork and every reformulation cost comes straight out of a thin margin with no compliance department to soak it up. A sugary-drink levy, a labelling mandate, or a safer-staffing standard lands here as a direct operating cost and, sometimes, as an opportunity — the pharmacy that delivers a smoking-cessation service, the practice paid to run screening. The proportionality test (best practice 2) and the regulatory-impact assessment (best practice 11) matter most to this group, because a rule whose fixed compliance cost is trivial for an enterprise can be ruinous for a single site, and because small providers rarely have the voice in consultation that large incumbents do.

Enterprise

A large provider, insurer, or manufacturer is both a subject of policy and a shaper of it. An enterprise absorbs the compliance cost of regulation, adjusts to fiscal levers, and often holds the data a government needs to evaluate a reform. It also has the resources to lobby, litigate, and reformulate — the very strategic behaviour policy must anticipate (best practice 9), and the source of capture risk. The mature enterprise stance is to engage transparently, treat regulation as a stable operating environment worth having rather than a cost to erode, and recognize that a well-designed rule which binds competitors equally can be a shared benefit rather than a pure burden.

Government

Government is the author of the toolkit and the actor of last resort for failures no market participant can fix. Its distinctive power is to tax, mandate, and pool at population scale; its distinctive discipline must be to weigh each intervention's own failure — regulatory capture, deadweight cost, gaming, regressivity — against the market failure it corrects, and to legislate for evaluation and reversibility. A ministry's hardest task is holding a line against concentrated industry pressure while spending diffuse public benefit, which is why standing institutions — HTA bodies, independent regulators, international treaties such as the Framework Convention on Tobacco Control — matter more than any single decision. Government also owns the equity account: it is answerable for who wins and who loses in a way no other actor is.

Common failure modes

• Instrument-first policy. Choosing a tax, a target, or a campaign because it is available or popular, without diagnosing the failure it is meant to correct. Fix: name the market failure first (Chapter 1.3 — Market Failure), then match the proportionate instrument to it.

• Overclaiming that prevention saves money. Selling a preventive programme on cost savings that arrive late, discounted, or never. Fix: appraise prevention like any treatment, and justify it on cost-effectiveness and equity, not on a promise of self-financing.

• Judging prevention on a one-year budget window. Testing a long-payback prevention programme against an annual budget-impact rule, so it fails a cash test it was never designed to pass. Fix: separate the affordability question (Chapter 2.5 — Budget Impact and Affordability) from the value question, appraise over the horizon on which the benefits actually accrue, and use public-health return-on-investment tools to make the long-lag payback visible.

• Confusing the population and high-risk strategies. Judging a whole-population measure by the small benefit it gives each individual, or expecting a high-risk programme to shift a population-level statistic. Fix: name which strategy the intervention is (the prevention paradox), and appraise it against the right yardstick — aggregate cases prevented for population measures, benefit per person treated for high-risk ones.

• Ignoring regressivity until an opponent names it. Launching a consumption tax without an equity account, then losing the argument on fairness. Fix: state the distributional incidence up front and design earmarking, exemptions, or transfers to offset it.

• Rolling out with no evaluation design. Implementing everywhere at once so no comparison is possible, leaving success a matter of assertion. Fix: phase where feasible, pre-register outcomes, collect baseline data, and commission independent appraisal.

• Underestimating strategic response and capture. Modelling behaviour as static and treating the regulator as neutral. Fix: assume the targeted industry will reformulate, substitute, relocate, and lobby, and build transparency and arm's-length institutions in from the start.

• Single-lever thinking. Expecting one instrument to carry a whole problem. Fix: combine reinforcing measures, model the package, and sequence popular measures first to build credibility for harder ones.

• No off-ramp. Legislating a tax, standard, or subsidy with no review, no data, and no power to adjust or withdraw. Fix: build in monitoring from day one, a sunset or review clause, and the legal ability to update rates and rules.

Maturity model

Checklist

• Name the specific market failure this policy corrects before choosing the instrument.
• Place the proposed instrument on the coercion spectrum and confirm it is the proportionate one.
• For any fiscal lever, base the design on elasticity and pass-through, and tax the harmful ingredient with a tier that rewards reformulation.
• Write the distributional incidence explicitly — who pays, who benefits — and design earmarking or exemptions to address regressivity.
• Appraise prevention with the same rigour as treatment; do not claim it saves money unless the evidence shows it.
• Identify any wrong-pockets or long-lag problem and design financing to bridge it.
• Design the evaluation before launch: baseline data, phased rollout where feasible, pre-registered outcomes, independent appraisal.
• Model the targeted industry's strategic response and build in transparency and arm's-length institutions against capture.
• Combine reinforcing instruments into a package and sequence them to build credibility.
• Complete a proportionate regulatory impact assessment, including the do-nothing option.
• Legislate a review date, monitoring duty, and the power to adjust or withdraw the measure.

Key sources

• World Health Organization — Framework Convention on Tobacco Control and guidance on fiscal policies for diet and non-communicable disease prevention — the standing international frameworks for tobacco and dietary policy.
• OECD — Health at a Glance and the OECD public-health and prevention economics series — comparative evidence on prevention spending and fiscal levers across countries.
• Geoffrey Rose — Sick Individuals and Sick Populations (1985) and The Strategy of Preventive Medicine — the origin of the prevention paradox and the population-versus-high-risk distinction that underpins prevention policy.
• NICE methods guidance (PMG36) and IQWiG, PBAC, and CADTH/CDA methods — national exemplars of health technology assessment as evidence-to-policy machinery.
• GOV.UK — Health economics: a guide for public health teams — a national exemplar of packaging health economics, including return-on-investment and prioritisation tools, for non-specialist decision-makers.
• HM Treasury — The Green Book (appraisal and evaluation in central government) — a standing framework for regulatory impact assessment and option appraisal.
• Economics Network — Health Economics for Teachers, health policy module — https://economicsnetwork.ac.uk/health/teachers

References

1. Health policy — Wikipedia — https://en.wikipedia.org/wiki/Health_policy
2. Public health — Wikipedia — https://en.wikipedia.org/wiki/Public_health
3. Regulation — Wikipedia — https://en.wikipedia.org/wiki/Regulation
4. Pigovian tax — Wikipedia — https://en.wikipedia.org/wiki/Pigovian_tax
5. Sin tax — Wikipedia — https://en.wikipedia.org/wiki/Sin_tax
6. Sugary drink tax — Wikipedia — https://en.wikipedia.org/wiki/Sugary_drink_tax
7. Externality — Wikipedia — https://en.wikipedia.org/wiki/Externality
8. Preventive healthcare — Wikipedia — https://en.wikipedia.org/wiki/Preventive_healthcare
9. Evidence-based policy — Wikipedia — https://en.wikipedia.org/wiki/Evidence-based_policy
10. Health technology assessment — Wikipedia — https://en.wikipedia.org/wiki/Health_technology_assessment
11. Regulatory capture — Wikipedia — https://en.wikipedia.org/wiki/Regulatory_capture
12. Framework Convention on Tobacco Control — Wikipedia — https://en.wikipedia.org/wiki/Framework_Convention_on_Tobacco_Control
13. World Health Organization — WHO Framework Convention on Tobacco Control — https://fctc.who.int/
14. OECD — Health at a Glance — https://www.oecd.org/health/health-at-a-glance.htm
15. NICE — Health technology evaluations: the manual (PMG36) — https://www.nice.org.uk/process/pmg36
16. GOV.UK — Health economics: a guide for public health teams — https://www.gov.uk/guidance/health-economics-a-guide-for-public-health-teams
17. Economics Network — Health Economics for Teachers — https://economicsnetwork.ac.uk/health/teachers
18. Rose G — Sick individuals and sick populations — International Journal of Epidemiology (1985) — https://doi.org/10.1093/ije/14.1.32